John A. Hermos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John A. Hermos has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Louis D. Fiore
Pharmacoepidemiology Research Group, Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston, MA and Department of Epidemiology, Youth Alcohol Prevention Center, Boston University School of Public Health, Boston, MA
2 shared publicationsMelissa M. Young
Pharmacoepidemiology Research Group, Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston, MA
2 shared publications- David R. Gagnon
Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
1 shared publication - David Rosenbloom
Boston University School of Public Health
1 shared publication Elizabeth V. Lawler
Pharmacoepidemiology Research Group, Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System and Department of Epidemiology, Youth Alcohol Prevention Center, Boston University School of Public Health, Boston, MA
1 shared publication
Latest Publications
- 22 October 2007
- Published by Wiley in Journal of Traumatic Stress
- Vol. 20 (5) , 909-914
Long‐term, high‐dose benzodiazepine prescriptions in veteran patients with PTSD: Influence of preexisting alcoholism and drug‐abuse diagnoses
Databases from the New England Veterans Integrated Service Network were analyzed to determine factors associated with long-term, high-dose anxiolytic benzodiazepine prescriptions dispensed to patients with posttraumatic stress disorder (PTSD) and existing alcoholism and/or drug abuse diagnoses. Among 2,183 PTSD patients, 234 received the highest 10% average daily doses for alprazolam, clonazepam, diazepam, or lorazepam, doses above those typically recommended. Highest doses were more commonly prescribed to patients with existing drug abuse diagnoses. Among patients with PTSD and alcoholism, younger age, drug abuse, and concurrent prescriptions for another benzodiazepine and oxycodone/acetaminophen independently predicted high doses. Results indicate that for veteran patients with PTSD, alcoholism alone is not associated with high-dose benzodiazepines, but existing drug abuse diagnoses do increase that risk.
- 22 October 2007
- Published by Wiley in Journal of Traumatic Stress
- Vol. 20 (5) , 909-914
Long‐term, high‐dose benzodiazepine prescriptions in veteran patients with PTSD: Influence of preexisting alcoholism and drug‐abuse diagnoses
Databases from the New England Veterans Integrated Service Network were analyzed to determine factors associated with long-term, high-dose anxiolytic benzodiazepine prescriptions dispensed to patients with posttraumatic stress disorder (PTSD) and existing alcoholism and/or drug abuse diagnoses. Among 2,183 PTSD patients, 234 received the highest 10% average daily doses for alprazolam, clonazepam, diazepam, or lorazepam, doses above those typically recommended. Highest doses were more commonly prescribed to patients with existing drug abuse diagnoses. Among patients with PTSD and alcoholism, younger age, drug abuse, and concurrent prescriptions for another benzodiazepine and oxycodone/acetaminophen independently predicted high doses. Results indicate that for veteran patients with PTSD, alcoholism alone is not associated with high-dose benzodiazepines, but existing drug abuse diagnoses do increase that risk.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (8) , 1229-1235
Patterns of Dispensed Disulfiram and Naltrexone for Alcoholism Treatment in a Veteran Patient Population
Background:Short‐term treatment trials indicate that two Food and Drug Administration–approved agents, disulfiram and naltrexone, may each curtail alcohol consumption, but two large 1‐year Veterans Administration cooperative studies showed no long‐term benefits for these agents over placebo. To assess whether these agents are being prescribed for extended periods, as an indicator of long‐term use in nonexperimental settings, we compared dispensing patterns in a veteran patient population.Methods:The New England Veterans Integrated Service Network outpatient pharmacy files between January 1, 1998, and June 30, 2001, were analyzed; only patients with prescriptions on or after March 1, 1998, were included. Measurements for each patient included data on new and refilled prescriptions of disulfiram, naltrexone, and control medications. Prescription survival curves with right censoring were constructed. Distinct treatment episodes were defined by having six or more months between the end date of a prior prescription and the start date of a new prescription.Results:From eight New England Veterans Integrated Service Network centers, 754 patients were dispensed disulfiram, and 971 were dispensed naltrexone, encompassing 873 and 1075 treatment episodes, respectively. Treatment episode durations were virtually identical for both drugs: more than 35% of episodes were 1 month or shorter, more than 50% were 2 months or shorter, and 75% were 5 months or shorter. Concurrently prescribed neuroleptic or statin medications predicted longer disulfiram and naltrexone treatment episodes. However, for patients newly prescribed common neuroleptic, antidepressant, or statin agents, the risks for discontinuing disulfiram or naltrexone were 1.4 to 2.3 times greater than for discontinuing these other agents.Conclusions:In clinical settings, veteran patients were likely to be dispensed either disulfiram or naltrexone for only several months or less. The contexts and reasons for these predominantly short‐term treatment episodes or the benefits derived were not known and merit further study.
- 1 August 2004
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 28 (8) , 1229-1235
Patterns of Dispensed Disulfiram and Naltrexone for Alcoholism Treatment in a Veteran Patient Population
Background:Short‐term treatment trials indicate that two Food and Drug Administration–approved agents, disulfiram and naltrexone, may each curtail alcohol consumption, but two large 1‐year Veterans Administration cooperative studies showed no long‐term benefits for these agents over placebo. To assess whether these agents are being prescribed for extended periods, as an indicator of long‐term use in nonexperimental settings, we compared dispensing patterns in a veteran patient population.Methods:The New England Veterans Integrated Service Network outpatient pharmacy files between January 1, 1998, and June 30, 2001, were analyzed; only patients with prescriptions on or after March 1, 1998, were included. Measurements for each patient included data on new and refilled prescriptions of disulfiram, naltrexone, and control medications. Prescription survival curves with right censoring were constructed. Distinct treatment episodes were defined by having six or more months between the end date of a prior prescription and the start date of a new prescription.Results:From eight New England Veterans Integrated Service Network centers, 754 patients were dispensed disulfiram, and 971 were dispensed naltrexone, encompassing 873 and 1075 treatment episodes, respectively. Treatment episode durations were virtually identical for both drugs: more than 35% of episodes were 1 month or shorter, more than 50% were 2 months or shorter, and 75% were 5 months or shorter. Concurrently prescribed neuroleptic or statin medications predicted longer disulfiram and naltrexone treatment episodes. However, for patients newly prescribed common neuroleptic, antidepressant, or statin agents, the risks for discontinuing disulfiram or naltrexone were 1.4 to 2.3 times greater than for discontinuing these other agents.Conclusions:In clinical settings, veteran patients were likely to be dispensed either disulfiram or naltrexone for only several months or less. The contexts and reasons for these predominantly short‐term treatment episodes or the benefits derived were not known and merit further study.
- 19 February 2004
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 350 (8) , 840-842
Opioid Therapy for Chronic Pain
Ballantyne and Mao's (Nov. 13 issue)1 recommendations for prescribing doses of short-acting opioids for chronic recurrent pain may put patients at increased risk both for undertreatment of their pain episodes and for drug tolerance. In treating occasional or recurrent pain, patients may be best advised to treat episodes early and aggressively with doses of opioids, or of nonopioids that are large enough to suppress their pain completely and for long intervals. Infrequent use of large doses of opioids is not a model for the development of drug tolerance, whereas the administration of smaller, repeated doses is.2
- 19 February 2004
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 350 (8) , 840-842
Opioid Therapy for Chronic Pain
Ballantyne and Mao's (Nov. 13 issue)1 recommendations for prescribing doses of short-acting opioids for chronic recurrent pain may put patients at increased risk both for undertreatment of their pain episodes and for drug tolerance. In treating occasional or recurrent pain, patients may be best advised to treat episodes early and aggressively with doses of opioids, or of nonopioids that are large enough to suppress their pain completely and for long intervals. Infrequent use of large doses of opioids is not a model for the development of drug tolerance, whereas the administration of smaller, repeated doses is.2